Axogen Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Axogen Inc (AXGN)
Axogen Inc stock price live, this page displays NASDAQ AXGN stock exchange data. View the AXGN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Axogen Inc real time stock price chart below.
What Is the Axogen Inc Stock Price Today?
The Axogen Inc stock price today is 51.35.
What Is the Stock Symbol for Axogen Inc?
The stock symbol for Axogen Inc is "AXGN."
What Stock Exchange Does Axogen Inc Trade On?
Axogen Inc is listed and trades on the NASDAQ stock exchange.
Is Axogen Inc a Good Stock to Buy?
Determining whether Axogen Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AXGN quote. (ISIN: US05463X1063)
What Is the Axogen Inc Stock Price Today?
The Axogen Inc stock price today is 51.35.
What Is the Stock Symbol for Axogen Inc?
The stock symbol for Axogen Inc is "AXGN."
What Stock Exchange Does Axogen Inc Trade On?
Axogen Inc is listed and trades on the NASDAQ stock exchange.
Is Axogen Inc a Good Stock to Buy?
Determining whether Axogen Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AXGN quote. (ISIN: US05463X1063)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
50.08
52.75
52 wk Range
23.00
52.91
AXGN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
50.0852.75
52 wk Range
23.0052.91
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AXGN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
59.09
Upside
+15.07%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Axogen Inc receives Investment Bank Analyst Rating Update- Investing.com
Pro
Axogen Inc receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Axogen Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Axogen Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Axogen Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Axogen Inc receives Investment Bank Analyst Rating Update- Investing.com
Pro- Axogen Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
11 Buy
0 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 59.09
(+15.07% Upside)
Axogen Inc SWOT Analysis
Nerve Repair Pionee | AxoGen leads in peripheral nerve injury solutions, with a growing $5.6 billion market and innovative products driving expansion into new segments like prostate care |
Financial Resilience | Q1 2025 revenue of $48.6M, up 17.4% YoY. Full-year guidance of $215.4M-$219.1M reaffirmed, projecting 15-17% growth. Analysts forecast $248M by 2026 |
Regulatory Catalyst | Anticipated BLA approval for Avance Nerve Graft in September 2025 could boost adoption, secure market exclusivity, and establish it as the standard of care |
Strategic Vision | New CEO Michael Dale's seven-point plan aims for cash flow positivity by 2025-2028, with $70M+ annual operational cash flow by 2028, self-funding future growth |
Axogen Inc Earnings Call Summary for Q3/2026
- AxoGen Q3 revenue rose 26.2% to $75.8M, beating estimates of $73.16M; adjusted EPS of $0.21 topped forecasts by 61.54%
- Company raised FY 2026 revenue guidance to at least $290M (29% growth); expects positive free cash flow and improved EBITDA margins
- BioCircuit acquisition adds NerveTape product, expected to contribute $7M in Q4 2026 and $34M in 2027 net of cannibalization
- Breast reconstruction segment surged 60%+; Avance Nerve Graft commercial coverage now reaches 96% of U.S. covered lives
- Shares jumped 20.53% premarket to $45.15; company plans prostate nerve reconstruction market entry in 2027
Last Updated: 2026-10-28, 09:04 a/m
Read Full TranscriptEarnings
Latest Release
Oct 28, 2026
EPS / Forecast
0.21 / 0.13
Revenue / Forecast
75.8M / 73.16M
Compare AXGN to Peers and Sector
Metrics to compare | AXGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAXGNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −97.6x | −1.1x | −0.3x | |
PEG Ratio | 0.08 | −0.12 | 0.00 | |
Price/Book | 6.3x | 2.6x | 2.6x | |
Price / LTM Sales | 11.7x | 2.1x | 2.8x | |
Upside (Analyst Target) | 13.2% | 106.1% | 67.2% | |
Fair Value Upside | Unlock | 0.1% | 10.1% | Unlock |
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Axogen Inc (AXGN) Stock Price Today?
The Axogen Inc stock price today is 51.35 USD.
What Stock Exchange Does Axogen Inc Trade On?
Axogen Inc is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Axogen Inc?
The stock symbol for Axogen Inc is "AXGN."
What Is the Axogen Inc Market Cap?
As of today, Axogen Inc market cap is 3.06B USD.
What Is Axogen Inc's Earnings Per Share (TTM)?
The Axogen Inc EPS (TTM) is -0.62.
When Is the Next Axogen Inc Earnings Date?
Axogen Inc will release its next earnings report on Feb 23, 2027.
From a Technical Analysis Perspective, Is AXGN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Axogen Inc Stock Split?
Axogen Inc has split 0 times.
How Many Employees Does Axogen Inc Have?
Axogen Inc has 622 employees.
What is the current trading status of Axogen Inc (AXGN)?
As of Nov 04, 2026, Axogen Inc (AXGN) is trading at a price of 51.35 USD, with a previous close of 49.50 USD. The stock has fluctuated within a day range of 50.08 USD to 52.75 USD, while its 52-week range spans from 23.00 USD to 52.91 USD.
What Is Axogen Inc (AXGN) Price Target According to Analysts?
The average 12-month price target for Axogen Inc is 59.09 USD, with a high estimate of 65 USD and a low estimate of 56 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +15.07% Upside potential.
What Is the AXGN Premarket Price?
AXGN's last pre-market stock price is 50.87 USD. The pre-market share volume is 2,620.00, and the stock has decreased by 1.37, or 2.77%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.